Replies to post #753129 on NorthWest Biotherapeutics Inc (NWBO)

[martyDg]

What's the use of all these patents if you don't have a single approved drug? Who gets the advantage of securing a patent? Definitely not retail only management.

[SkyLimit2022]

zero82,

Thanks for reposting your keen insights 😶

Roswell may prove to be HUGE too in terms of “building a value proposition” …

Price and value do not always align—that is the principle behind investing in advance of a catalyst or series of catalysts…






Leveraging partnerships with world-renowned research institutions, such as Roswell Park in New York, and peer-reviewed grants from U.S. government agencies, such as the NIH, is both efficient and crucial in supporting the validity of breakthrough science and building value.

The trial that just posted a quality control update on Feb 24, 2025 and is led by Dr. Puzanov as principal investigator is quite noteworthy.

https://clinicaltrials.gov/study/NCT04093323






https://physicianresources.roswellpark.org/news/roswell-park-clinical-trials-offer-novel-immunotherapies-for-advanced/metastatic-tumors-refractory-melanoma

An overarching consideration regarding the potential commercialization of a dendritic cell platform includes those products that are already commercialized in the U.S. and other nations around the world. For example, consider the expanding market for checkpoint inhibitors like pembrolizumab (PD-1 blockade technology has only been on the market for about 10 or 11 years, but its value is already vast and growing).

NWBO owns three distinct patent-fortified DC product platforms that we currently know about:

1. DCVax-L
2. DCVax Direct
3. Roswell’s DC Platform

4. Additionally, we might consider the novel EDEN manufacturing technology, which NWBO acquired through its strategic acquisition of Flaskworks in 2020.

Currently, two of the novel platform technologies owned by NWBO are in combo trials at UCLA and at Roswell Park. The combo trials include a highly profitable commercial product—Merck’s pembrolizumab, the studies have reached PII, interim efficacy data are beginning to emerge, and the three combo studies (one at UCLA and two at Roswell) are supported by continuing peer-reviewed grants awarded by the U.S. NIH and the U.S. DoD.

⭐️Combo is King!⭐️

Is is also quite noteworthy that the term “tumor-agnostic” was used in reference to the Roswell DC product platform:




https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm




https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927

https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/

[RobotDroid]

Best to not suffer fools, especially on a Friday. Put that asshat on ignore.

[Doc logic]

Investor082,

Ever notice that a room at night is usually pretty dark and you can’t really see what’s in it until you flip a switch or maybe you prefer the sunrise over the Grand Canyon after a New Moon night analogy?; ). Best wishes.

[XMaster2023]

What is huge is the amount of naked shorts that will be counted during discovery. What is huge is the settlement the market makers will offer when the realize their pants are between their ankles.